Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AQST · NASDAQ · Pharmaceutical Preparations
Aquestive Therapeutics (AQST) · oqro.io/stocks/AQST · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$3.91+0.34 (+9.52%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Aquestive Therapeutics (AQST) filed 2 open-market purchases in the last 90 days; the latest was filed on Nov 12, 2026.
Since 2018, Aquestive Therapeutics insiders reported 36 open-market purchases and 18 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
In the last 90 days, 1 insider of Aquestive Therapeutics (AQST) reported 1 open-market sale worth $106K in total on SEC Form 4. The largest seller by value was Daniel Barber, with $106K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Aquestive Therapeutics (AQST) was disclosed by a member of Congress in the last 12 months.
Aquestive Therapeutics's next results are expected on Mar 2, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−26.2% (−$1.39) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $5.30 on Nov 13, 2025 to $3.91 on Nov 13, 2026 (−26.2%). Disclosed in this range: 2 insider trades, 1 pre-arranged insider sale, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Warren, Nj.
Last 12 months
−26.2%
Market value
$491M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 29.3M shares sold short (23.3% of shares outstanding), +6.2% vs the previous count, 13.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$7.56M
−41.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$40.7M
This quarter −$7.63M, a year earlier −$12.9M
Net cash
$35.3M
Debt $55M, cash $90.3M, at Sep 30, 2026
Net income, last 12 months
−$79.3M
Operating profit covers interest -5.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Revenue, fiscal 2025
$44.5M
−22.6% vs the year before
Net income, fiscal 2025
−$83.8M
A loss for the year
Shares outstanding
126M
As of Oct 30, 2026
Traded Nov 10, 2026 · largest single transaction ~$95K
Nov 10, 2026~$95K · 27K sh @ $3.55
Nov 10, 2026~$4.2K · 1,200 sh @ $3.53
DetailsOfficial recordFund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Written by software from the filings listed below · Nov 13, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeLast results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Mar 2, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
80%
28 of 35 insider purchases since 2018 came within 30 days after a results announcement
From Aquestive Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Aquestive Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insiders of Aquestive Therapeutics reported 36 open-market purchases and 18 sales since 2018; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $99K2×2 trades | $106K1×1 trade |
| 2025 | — | $1.01M5×5 trades |
| 2024 | — | $430K3×3 trades |
| 2022 | $152K5×5 trades | — |
| 2021 | — | $501K3×3 trades |
| 2020 | $25K2×2 trades | $968K6×6 trades |
| 2019 | $173K13×13 trades | — |
| 2018 | $2.78M14×14 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 11, 2025, AQST is down 31.3% and the index fund is up 10.4%: 42 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AQST moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
